Phase I Clinical Trial and Pharmacokinetic Study

infusion solutions are compatible with PVC i.v. infusion bags and are chemically stable ... two cycles of treatment. Disease assessments by any tech- ...

2 downloads 0 Views 168KB Size

Recommend Documents

Apr 9, 2017 - to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.

In a phase 2 study of raltitrexed, cisplatin, and 5- fluorouracil administered to .... nitroacetanilide, was obtained from Sigma-Aldrich (Milwaukee,. WI). Twenty-five ...

Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with. Advanced Cancer1. Sridhar Mani,2 ...

Val and 5-methylbenzoic acid form the lateral chain. The cycled region ...... (M)/prednisone (P) in men with androgen independent prostate cancer. J Clin Oncol ...

POH was formulated in soft gelatin capsules con- .... Drug Formulation. ... phase I design. .... No significant problems with myelosuppression were seen. Grade 1 ...

(/')determined the human pharmacokinetics of the drug on a. 6-h infusion ..... dexamethasone, and/or aminophylline were required to treat the reactions.

staurosporine family of agents, which have two indole nitrogens linked to a carbohydrate residue. Representatives from both of these subgroups have been the ...

p.o., but this route of administration has several limitations. The bioavailability of MP is low. (approximately. 16%), and the resulting plasma concen- trations exhibit ..... for the tram- fer ofTG toand from the peripheral compartment;. Xe,, the am

in Serum of Cancer Patients: Phase I Clinical Trial. Jose A. Baptista,1 ... (1), sub- sequently from. North. American plants of the ganera. Astragulus .... Gal in H20.

Center, Salt Lake City, UT; Grant CA 26126, Robert Wells of the. Children's Hospital ..... Giguere, V., Ong, E. S., Segui, P., and Evans, R. M. Identification of a receptor for the .... Brazell, R. K., Vane, F. M., Ehmann, C. W., and Colburn, W. A..

Apr 12, 2017 - Sorafenib (Nexavar) is an orally bioavailable small-mol- ecule inhibitor (molecular weight, 465 g/mole) of multiple kinases controlling tumor ...

Robert J. Motzer,2 Subhash C. Gulati, William P.Tong, Celia Menendez-Botet, Peter ... •'the Department of Clinical Chemistry [C. M-B.j: and the Department of ...

starting dose of POH was 1600 mg/m2/dose, with escala- tions to 2100 ...... Elegbede, J. A., Elson, C. E., Qureshi, A., Tanner, M. A., and Gould,. M. N. Inhibition of ...

Jul 15, 2006 - suggested that G1 arrest induced by EGFR TKI interferes with the cell cycle .... Dassonville O, Formento JL, Francoual M, et al. Expression of ...

derived from breast (MDA-MB-435), colorectal (RKO, HT-29, ..... 2019. 625. 1857. 1077. 4208. 2903. 2434. Ctrough e (ng/ml). Ro 31-7453. 54.2. 145. 72. 361.

C. G. Haase5, D. Voliotis5 & D. Strumberg2* ... 38-3441 either at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600mg/m2/day for 1 day every. 3 weeks ..... 38-3441. Plasma samples were analyzed for BAY 38-3441 and CPT using.

May 15, 2009 - Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour ... Authors' Affiliations: 1Institute for Drug Development, Cancer Therapy ...

standard samples containing blank plasma spiked with prino- mastat and AG3473 were ... An API III Perkin-Elmer Sciex LC/MS using positive ion electrospray ...

feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when ...... This contrasts with the nonlinear pharmacokinetic profile of paclitaxel (20).

Abstract. Purpose: VNP40101M is a novel sulfonylhydrazine al- kylating agent with broad antitumor activity in animal mod- els. As alkylating agents are ...

Dec 15, 2005 - Anthony W.Tolcher,1and Eric K. Rowinsky1. Abstract Purpose:To ...... Tricoli JV, Sahai BM, McCormick PJ, Jarlinski SJ,. Bertram JS, Kowalski D.

Oct 13, 2009 - pared with prior studies of the parental antibody hu3S193. These results ... humanized monoclonal antibody based on the anti-Ley anti-.

This regimen deserves further evaluation to define its antitumor activity .... DLT was defined as any of the ..... Karenitecin is the first compound of this type to be.

Dugan, M. A phase I study of SCH 52365 (temozolomide) in adult patients with .... Fletcher, W. S., Daniels, D. S., Sondak, V. K., Dana, B., Townsend,. R., Hynes ...